Alvotech (ICE:ALVO)

Market Cap	301.39B
Revenue (ttm)	68.10B
Net Income (ttm)	7.67B
Shares Out	n/a
EPS (ttm)	26.33
PE Ratio	39.29
Forward PE	17.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,384
Average Volume	79,851
Open	974.00
Previous Close	978.00
Day's Range	966.00 - 974.00
52-Week Range	970.00 - 1,945.00
Beta	0.10
RSI	37.26
Earnings Date	Nov 12, 2025

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 1,012
• Stock Exchange: Nasdaq Iceland
• Ticker Symbol: ALVO

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Financial numbers in USD